Fullerton, CANCT07299019Now EnrollingIRB Ready

Secondary Progressive Multiple Sclerosis Clinical Trial in Fullerton, CA

Access cutting-edge secondary progressive multiple sclerosis treatment through this clinical trial at a research site in Fullerton. Study-provided care at no cost to qualified participants.

Sponsored by Zenas BioPharma (USA), LLC

Quick Self-Assessment

See if you qualify for this Fullerton location

Preparing your pre-screening questions…

Expert Care in Fullerton

Access secondary progressive multiple sclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related secondary progressive multiple sclerosis treatment provided free

Apply for This Fullerton Location

Check if you qualify for this secondary progressive multiple sclerosis clinical trial in Fullerton, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fullerton

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fullerton site if eligible
  4. 4Begin participation

About This Secondary Progressive Multiple Sclerosis Study in Fullerton

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Sponsor: Zenas BioPharma (USA), LLC

Who Can Participate

Inclusion Criteria

18 to 60 years of age, inclusive, at the time of signing the informed consent.
Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
Absence of clinical relapses for at least 24 months.

Exclusion Criteria

The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
History or current diagnosis of other neurological disorders that may mimic MS
History or current diagnosis of progressive multifocal leukoencephalopathy
Active, clinically significant viral, bacterial, or fungal infection
History of any other significant active medical condition
History of suicidal behavior within 6 months prior to Screening
Any prior history of malignancy
Patients on anticoagulation, or antiplatelet therapy
Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
Clinically significant laboratory abnormalities at Screening.
Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fullerton?

Yes, this clinical trial (NCT07299019) has an active research site in Fullerton, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Secondary Progressive Multiple Sclerosis Treatment Options in Fullerton, CA

If you're searching for secondary progressive multiple sclerosis treatment options in Fullerton, CA, this clinical trial (NCT07299019) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fullerton research site is actively enrolling participants for this clinical trial. You'll receive care from experienced secondary progressive multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all secondary progressive multiple sclerosis clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Fullerton, CA

See all multiple sclerosis clinical trials recruiting in Fullerton — not just this study.

Browse Multiple Sclerosis Trials in Fullerton →

Browse More Trials by Condition

Multiple Sclerosis TrialsAll Conditions →

Ready to Join in Fullerton?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fullerton, CA